Search results for "Metabolic disease"

showing 10 items of 778 documents

Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial.

2011

Objectives: Apolipoprotein (Apo)B, ApoA-I, and their ratio could predict coronary heart disease (CHD) risk more accurately than conventional lipid measurements. Our aim was to assess the effect of a traditional Mediterranean diet (TMD) on apolipoproteins. Methods: High-cardiovascular risk subjects (n=551, 308 women and 243 men), aged 55-80 years, were recruited into a large, multicenter, randomized, controlled, parallel-group, clinical trial (The PREDIMED Study) aimed at testing the efficacy of TMD on primary cardiovascular disease prevention. Participants assigned to a low-fat diet (control) (n=177), or TMDs (TMD. +. virgin olive oil (VOO), n=181 or TMD. +. nuts, n=193) received nutritiona…

MaleApolipoprotein BMediterranean dietCoronary DiseaseDiet MediterraneanDieta mediterràniaApolipoprotein B/A-I ratiolaw.inventionCohort StudiesRandomized controlled triallawVirgin olive oilMedicineNutsCardiometabolic riskAged 80 and overBioquímica y tecnologíabiologyAnthropometryMiddle AgedLipidsBiochemistry and technology0021-9150virgin olive oilApolipoproteïnesFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineApolipoprotein BCohort studyRiskmedicine.medical_specialtyApolipoprotein B/A-IBioquímica i biotecnologiaInternal medicineMediterranean dietHumansPlant OilsOlive OilAgedApolipoproteins BApolipoprotein A-Ibusiness.industrynutritional and metabolic diseasesApolipoproteins bCardiometabolic riskClinical trialEndocrinologybiology.proteinbusinessOlive oil
researchProduct

Multivariate analysis on complications of central venous access devices in children with cancer and severe disease influenced by catheter tip positio…

2019

Abstract Context Reliable long-term central venous access device (CVAD) is essential for the management of pediatric patients with cancer or chronic diseases. However, there is no general consensus for optimal catheter tip location and vessel insertion site in children. Objective This single center study analyzes the risk of complications associated with long-term upper body CVAD and evaluates them with respect to catheter tip location as well as vessel insertion site. Design Pediatric patients who received long-term upper body CVAD from January 2008 through April 2017 and underwent radiographic documentation of the tip location were retrospectively included in the study. Data on demographi…

MaleCatheterization Central Venousmedicine.medical_specialtyAdolescentmedicine.medical_treatmentContext (language use)03 medical and health sciencesPostoperative Complications0302 clinical medicineMetabolic DiseasesNeoplasms030225 pediatricsOcclusionmedicineHumansChildRetrospective StudiesBronchusbusiness.industryInfant NewbornInfantPrognosisHematologic DiseasesPediatric cancerSurgeryCathetermedicine.anatomical_structureImmune System DiseasesOncologyChild Preschool030220 oncology & carcinogenesisRight Main BronchusFemaleSurgeryComplicationbusinessCentral venous catheterFollow-Up StudiesSurgical Oncology
researchProduct

Cardiovascular fitness in youth: association with obesity and metabolic abnormalities

2014

[ES] Las terapias que se implantan actualmente para la obesidad se centran en los aspectos nutricionales y sobre la actividad física. Con el fin de hacer que la actividad física sea una terapia positiva en vez de un desencadenador de discapacidades, es relevante evaluar de forma precisa el entrenamiento cardiovascular. Objetivo: evaluar el entrenamiento cardiovascular midiendo el consumo máximo de oxígeno y evaluar su relación con los parámetros cardiometabólicos clásicos. Métodos: se aplicó el protocolo modificado de Balke a 126 individuos caucásicos (60 % de varones), con edades entre 9 y 16 años, que se sometieron a una evaluación de obesidad. El grupo de no obesos consistía de individuo…

MaleChildren and adolescentsEntrenamiento cardiovascularAdolescentAnaerobic ThresholdExercise testObesidadAdolescentsTECNOLOGIA ELECTRONICAMetabolic DiseasesPredictive Value of TestsHumansCorObesityCardiovascular fitnessChildNiños y adolescentesNutriciólcsh:RC620-627Sistema cardiovascularTrastorns de la nutrició en els infantsVO2 peaklcsh:Nutritional diseases. Deficiency diseasesPhysical FitnessVO2 máximoExercise TestObesitatFemalePrueba de esfuerzoInfantsNutrición Hospitalaria
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct

A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses

2014

Background: Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its complications. The natural history of complicated coeliac disease is characterised by two different types of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases. Methods: Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and sex- and age-matched coeliac p…

MaleComplicationsSettore MED/09 - Medicina InternaLymphomaSmallGastroenterologyCoeliac diseaseEnteropathy-Associated T-Cell LymphomaIntestine SmallMedicineCeliac diseaseEnteropathyTreatment FailureINTESTINAL T-CELL LYMPHOMAGastroenterologyGLUTEN FREE DIETGeneral Medicinecomplicated coeliac disease; natural history; prognosis;IleitisMiddle AgedPrognosisEnteritisIntestineNatural historyAdult; Aged; Carcinoma; Case-Control Studies; Celiac Disease; Collagenous Sprue; Disease Progression; Enteritis; Enteropathy-Associated T-Cell Lymphoma; Female; Humans; Ileitis; Intestinal Neoplasms; Intestine Small; Jejunal Diseases; Lymphoma B-Cell; Male; Middle Aged; Prognosis; Treatment Failure; Diet Gluten-Freenatural historyGluten-free dietDisease ProgressionEnteropathy-associated T-cell lymphomaFemaleprognosiResearch ArticleCollagenous SprueAdultmedicine.medical_specialtyLymphoma B-CellGlutensSettore MED/12 - GASTROENTEROLOGIAcomplicated coeliac diseasecomplications/drug therapy/mortality Myocytes; celiac diseaseNODiet Gluten-FreeInternal medicineIntestinal NeoplasmsHumanscomplications/drug therapy/mortalitySurvival rateCELIAC DISEASE; Complications; INTESTINAL T-CELL LYMPHOMA; prognosis; GLUTEN FREE DIETAgedcomplications/drug therapy/mortality; Myocytes; celiac diseaseMyocytesbusiness.industryCarcinomaB-CellCase-control studynutritional and metabolic diseasesJejunal DiseasesHepatologymedicine.diseasedigestive system diseasesDietEATLCase-Control StudiesGluten-FreeGluten freebusinessComplicationcoeliac disease
researchProduct

The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

2022

Background: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 20…

MaleDEATHSDALY cancer risk factorsMedizinsystematic analysisGlobal HealthRisk AssessmentCancer preventionGlobal Burden of DiseaseRC0254Risk-attributable cancer deathsSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineQuality-Adjusted Life YearNeoplasmscancerHumansGlobal Burden of Disease StudyUKMedicine(all)MCCRC0254 Neoplasms. Tumors. Oncology (including Cancer)Risk FactorSmokingCOVID-193rd-DASGeneral MedicineDisability-adjusted life-yearsSOCIAL DETERMINANTSRisk assessmentsrisk factorCardiovascular and Metabolic Diseases3121 General medicine internal medicine and other clinical medicineOBESITYCancer burden/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNeoplasmFemaleLIFE-STYLEQuality-Adjusted Life YearsHEALTHRAHumanRC
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

2021

[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD.

MaleDiseaseBody Mass IndexCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseAdult Body Mass Index Cohort Studies Fatty liver Female Humans Male Middle Aged Non-alcoholic Fatty Liver Disease Non-alcoholic steatohepatitis Prognosis Survival Rate Thinness Whitesnonalcoholic steatohepatitis2. Zero hunger0303 health sciencesFatty liverNASHGastroenterologyMiddle AgedPrognosis3. Good healthSurvival RateCohort030211 gastroenterology & hepatologyFemalemedicine.symptomAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAdigestive systemWhite People03 medical and health sciencesThinnessNAFLDInternal medicinemedicineHumansPNPLA3030304 developmental biologyfatty liverbusiness.industryWhitesSettore MED/09 - MEDICINA INTERNAnutritional and metabolic diseasesmedicine.diseaseLean-NASHObesitydigestive system diseasesLean-OutcomesSteatohepatitisbusinessWeight gainBody mass index
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Polygenic Score for Physical Activity Is Associated with Multiple Common Diseases

2021

Supplemental digital content is available in the text.

MaleEpidemiologyPhysical fitnessType 2 diabetesDiseaseLogistic regressionTYPE 2 DIABETESOrthopedics and Sports Medicine315 Sport and fitness sciencesPREDICTORSChildkohorttitutkimusFinlandAged 80 and oversairastavuusHERITABILITYGenetic PleiotropyriskitekijätMiddle AgedCardiovascular DiseasesChild PreschoolCohortComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleSMOKINGgeneettiset tekijätfyysinen aktiivisuusAdultGenetic Markerskuolleisuusmedicine.medical_specialtyAdolescentGenotypePhysical Therapy Sports Therapy and RehabilitationEXERCISEpitkittäistutkimusLower riskRisk AssessmentYoung AdultMetabolic DiseasesInternal medicineClinical Decision RulesBENEFITSmedicineHumansAgedbusiness.industryRISK SCORESCardiometabolic Risk FactorsInfantOdds ratiomedicine.diseaseGENEBODY-MASS INDEXLogistic ModelsCase-Control StudiesLinear Modelssydän- ja verisuonitauditbusinessBody mass indexGenome-Wide Association Study
researchProduct